BMJ  2007;335:1064 (24 November), doi:10.1136/bmj.39405.459074.4E

News

In Brief

News

The first 150 words of the full text of this article appear below.

Use of osteoarthritis drug is suspended in UK: The UK Medicines and Healthcare Products Regulatory Agency has suspended sales of the osteoarthritis drug lumiracoxib (Prexige), pending a Europe-wide review next month. The latest global safety data have shown an increase in the risk of serious liver problems with the licensed dose of 100 mg—in some cases after treatment of less than a month. Around 5000 UK patients have received the drug since it became available in 2005, and 8.5 million prescriptions have been written worldwide. (See www.mhra.gov.uk.)

Additional box warning for rosiglitazone: GlaxoSmithKline has agreed to upgrade the information in its warning box on rosiglitazone (Avandia), a drug approved in 1999 for the treatment of type 2 diabetes. The warning refers to a meta-analysis of 42 clinical studies involving 14 327 patients that showed an increased risk of ischaemic heart attacks and angina, but it states that the available . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Diabetes expert accuses drug company of "intimidation"
Bob Burton
BMJ 2007 335: 1113. [Extract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ